Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 20, 2023 -- There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia & Lymphoma.
Shanna Arnold Egloff, Ph.D., from HCA Healthcare in Nashville, Tennessee, and colleagues describe clinical presentation, patient-related factors, prognostic characteristics, treatment patterns, clinical outcomes and resource utilization among 200 patients with HR-MDS within a large U.S. community hospital network.
The researchers found that patients with HR-MDS treated in the community setting were elderly, with a median age of 76 years, and had a high comorbidity burden. First-line therapy was hypomethylating agent (HMA) monotherapy, lenalidomide, and venetoclax (20, 2, and 2 percent, respectively); the remaining patients were treated with supportive care. Within six months of diagnosis, 61 percent of the patients were hospitalized. The overall survival was 11.8 months. Curative transplantation was rarely used, there was underutilization of HMA-based therapy, and responses were not durable. In addition, most of the patients became transfusion-dependent or transformed to acute myeloid leukemia. Resource utilization was considerable and was highly linked with in-hospital days.
"Our experience confirms that newer approaches to HR-MDS will need to emphasize favorable logistics and coordination of care delivery as well as identify novel therapies with reduced toxicity in an elderly and high comorbidity population to enhance persistence with therapy," the authors write.
Several authors disclosed ties to HCA Healthcare.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Review Explores Cutaneous Manifestations of Myelodysplastic Syndrome
FRIDAY, April 19, 2024 -- Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and...
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 -- Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell...
Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
TUESDAY, Jan. 9, 2024 -- For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.